Diagnostic News and Research

RSS

New partnership to deliver world-class healthcare through collaborative scientific research

A new partnership which harnesses world-class expertise will ensure patients benefit sooner from new treatments, diagnostics and prevention strategies.

9 Oct 2015

ED physicians make key changes in clinical decision-making after viewing CT scan results

A study from the Massachusetts General Hospital Institute for Technology assessment finds that, after viewing CT scan results, physicians in the emergency departments of four major academic medical centers made key changes in clinical decision-making for patients with symptoms frequently seen in emergency rooms.

9 Oct 2015

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1. Keytruda is approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

9 Oct 2015

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient's immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

9 Oct 2015

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

To honor six cancer survivors featured in its newest international ad campaign, NanoString Technologies, Inc. will donate $6,000 to the American Cancer Society. The “Dear Cancer Researcher” participants courageously shared their personal stories of triumph to help the biotechnology company launch its newest product, nCounter SPRINT™ Profiler, a system that gives researchers the tools and opportunity to think beyond current everyday practice.

From NanoString Technologies 9 Oct 2015

NIBIB-supported bioengineers work to reduce platelet activation and clotting in patients with VADs

A team of NIBIB-supported bioengineers, aerospace scientists, and cardiovascular clinicians are improving the function of the thousands of life-saving ventricular assist devices (VADs) implanted in advanced heart failure patients each year.

8 Oct 2015

New book suggests ways to reduce medical reversals

Medical reversal—when accepted medical interventions are abandoned because they are found to be ineffective—is the "most important problem in medicine today," according to the authors of a new book: Ending Medical Reversal.

8 Oct 2015

Scientists identify culprit genes behind the formation and progression of breast tumours

A team from the SingHealth Duke-NUS Academic Medical Centre, comprising scientists and clinicians from the National Cancer Centre Singapore, Singapore General Hospital and Duke-NUS Graduate Medical School, has uncovered the genetic landscape of a distinct breast tumour group called fibroepithelial tumours.

8 Oct 2015

New microscope technology may help surgeons work with greater accuracy

Researchers at the University of Arizona have developed a prototype of a new microscope technology that could help surgeons work with a greater degree of accuracy. The new technology, call augmented microscopy, overlays images depicting diagnostic information such as blood flow and cancerous tissue over real images of blood vessels and other tissues and structures being viewed in the microscope.

8 Oct 2015

Claritas Genomics announces launch of Claritas Clinical Exome, novel diagnostic test

Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver confirmed results for a patient’s clinical whole exome within 4 weeks, compared to the industry standard of 12 weeks or more. Patients with rare disease typically seek a diagnosis for 8-12 years, receiving 3-5 separate tests at a high cost.

7 Oct 2015

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Myriad Genetics, Inc. (NASDAQ: MYGN) has announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

7 Oct 2015

Invitae announces dramatic expansion of genetic testing menu

Invitae Corporation (NYSE: NVTA), a genetic information company, has announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will begin releasing the new content between now and the end of the year. Invitae is immediately expanding its menu with dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric and other rare disorders.

7 Oct 2015

Use of chest CT scans for hospital emergency-room patients with blunt trauma can be reduced: Study

Use of computed tomography (CT) scans of the chest for hospital emergency-room patients with blunt trauma could be reduced by more than one-third without compromising detection of major injury, concludes a new study led by a UC San Francisco physician.

7 Oct 2015

UC Davis researchers awarded $15.5 million to develop world's first total-body PET scanner

A UC Davis research team has been awarded $15.5 million to build the world's first total-body positron emission tomography (PET) scanner, which could fundamentally change the way cancers are tracked and treated and put the university on the nation's leading edge of molecular imaging.

7 Oct 2015

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

Luminex Corporation today announced that it has received FDA clearance for the company's ARIES® System and ARIES HSV 1&2 Assay.

7 Oct 2015

New diagnostic technology based on computer algorithms can quickly identify source of cancer

In by far the majority of cancer cases, the doctor can quickly identify the source of the disease, for example cancer of the liver, lungs, etc. However, in about one in 20 cases, the doctor can confirm that the patient has cancer—but cannot find the source. These patients then face the prospect of a long wait with numerous diagnostic tests and attempts to locate the origin of the cancer before starting any treatment.

7 Oct 2015

New nanometer-scale DNA machine can be used for detecting HIV diagnostic antibodies

New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Cardiovascular disease risk can now be predicted for teens

Risk for cardiovascular disease, currently running rampant in the United States, can now be predicted for adolescents thanks to a new diagnostic test developed by a University of Virginia Children's Hospital pediatrician and his collaborators. The test accounts for many risk factors for the deadly disease and has the potential to be adapted by physicians nationwide to assess teenagers' future risk and encourage the healthy behaviors that could save their lives.

7 Oct 2015

Agfa HealthCare awarded new three-year DR contract with Premier, Inc.

Agfa HealthCare announced today that it has been awarded a new three-year group purchasing contract with Premier, Inc., a leading healthcare improvement company, to provide its entire product line of digital radiography (DR) solutions to the alliance's approximately 3,600 member hospitals and 120,000 other alternate healthcare sites in the United States.

From Agfa HealthCare 7 Oct 2015

Diagnostic News and Research

New partnership to deliver world-class healthcare through collaborative scientific research

ED physicians make key changes in clinical decision-making after viewing CT scan results

FDA grants accelerated approval for Keytruda to treat patients with advanced NSCLC

Immunovia and OHSU team up to validate, commercialize blood test for early diagnosis of pancreatic cancer

NanoString Technologies will donate to honor cancer survivors featured in its newest campaign

NIBIB-supported bioengineers work to reduce platelet activation and clotting in patients with VADs

New book suggests ways to reduce medical reversals

Scientists identify culprit genes behind the formation and progression of breast tumours

New microscope technology may help surgeons work with greater accuracy

Claritas Genomics announces launch of Claritas Clinical Exome, novel diagnostic test

Myriad Genetics and Tufts Health Plan sign agreement to cover Prolaris® for members with localized prostate cancer

Invitae announces dramatic expansion of genetic testing menu

Use of chest CT scans for hospital emergency-room patients with blunt trauma can be reduced: Study

UC Davis researchers awarded $15.5 million to develop world's first total-body PET scanner

Luminex receives rapid clearance from FDA for ARIES System and ARIES HSV 1&2 Assay

New diagnostic technology based on computer algorithms can quickly identify source of cancer

New nanometer-scale DNA machine can be used for detecting HIV diagnostic antibodies

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Cardiovascular disease risk can now be predicted for teens

Agfa HealthCare awarded new three-year DR contract with Premier, Inc.

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News